Saturday 10 October 2026 Export all IDXG data to Excel Powerpack

Interpace Biosciences, Inc.

IDXG

Interpace Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $38.7 million, down 17.5% from fiscal 2024. In the quarter to June 2026, revenue fell 1.09%, EPS grew 104.1% and free cash flow fell 92.1%, each against the same quarter a year earlier. Operating cash flow growth for five consecutive years.

6.00 0.00 0.00%

Follow IDXG

Alert me

Market cap: —
P/E: 0.2×
Fwd P/E: —
Dividend yield: —
F-score: 5/9
Altman Z: −6.95
Beneish M: 2.07
Dividend safety: n/a

Overview Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership —

Capital & Financial Ratios $m

Market Cap —

Revenue 36.14

Net Income 24.45

Free Cash Flow 4.10

Net Debt (2.69)

Current Ratio 2.22

Debt/Equity 0.00

P/E ratio 0.22

Fwd P/E —

P/S ratio 0.92

P/B ratio 1.42

Past 5Y EPS Growth —

This Y EPS Growth —

Next Y EPS Growth —

Next Y revenue growth —

Next 5Y EPS Growth —

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	3	1	3	3
Receivables	5	9	6	6
Inventory	—	—	—	—
Other	2	2	2	2
	10	12	10	11

	2023	2024	2025	Q'26
Payables	2	2	1	2
ST’ Debt	—	—	—	—
Other	—	—	—	—
	11	11	5	5

Compound Annual Growth %

	10y	5y	3y
Sales	15.17%	3.63%	6.75%
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	5.54%	0.00%	0.00%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	9	9	—	—	—
’25	12	9	9	9	39
’24	10	12	12	12	47
’23	10	11	9	10	40
’22	8	7	8	8	32
’21	10	11	8	4	33
’20	9	5	8	10	32

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	0	0	—	—	—
’25	1	1	2	2	6
’24	0	1	2	1	5
’23	1	0	1	1	4
’22	(1)	(3)	(3)	0	(8)
’21	(5)	(2)	(1)	(1)	(9)
’20	(7)	0	(6)	(2)	(14)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	0	0	—	—	—
’25	1	1	2	2	5
’24	0	1	2	1	4
’23	1	0	1	1	3
’22	(1)	(3)	(3)	0	(8)
’21	(5)	(2)	(1)	(1)	(9)
’20	(7)	0	(6)	(2)	(16)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	0.15	0.03	—	—	—
’25	0.30	(0.70)	0.15	4.70	4.45
’24	0.55	2.30	1.45	(3.34)	2.00
’23	0.40	0.20	(0.70)	2.34	0.90
’22	(2.65)	(4.65)	(16.75)	(1.85)	(25.90)
’21	(5.15)	(4.20)	(4.25)	(4.45)	(18.07)
’20	(11.60)	(6.80)	(7.70)	(10.05)	(36.60)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	—	—	—	—	—	—	1.01	0.44	Analyst estimates 2026–2028 Powerpack
	High	—	—	—	—	—	—	—	—	3.54	2.70
People
People	Employees	61	75	89	178	152	147	94	108	111	102
	Revenue/emp, $m	0.21	0.21	0.25	0.14	0.21	0.23	0.34	0.37	0.42	0.38
Income, $m
Income, $m	Revenue	13	16	22	24	32	33	32	40	47	39
	Gross margin, %	49.25	53.71	53.43	34.40	33.10	56.78	57.26	62.58	63.77	62.31
	EBT	(9)	(13)	(13)	(27)	(26)	(8)	(6)	2	7	4
	EBT margin, %	(65.51)	(82.61)	(58.01)	(110.16)	(80.71)	(23.38)	(18.33)	5.70	14.81	9.74
	Net income	(8)	(12)	(13)	(27)	(26)	(15)	(22)	2	7	25
	Depreciation	4	4	4	5	6	5	12	2	1	1
Per share, $
Per share, $	Revenue	360.47	50.42	38.88	32.33	40.21	40.04	37.56	46.37	53.48	43.77
	Earnings	(229.50)	(38.50)	(21.50)	(36.25)	(36.60)	(18.05)	(25.90)	0.95	7.10	27.75
	Cash flow	(209.56)	(48.41)	(15.40)	(25.30)	(17.35)	(10.54)	(9.07)	4.39	5.30	6.59
	Capex	0.00	(0.09)	(0.80)	(18.62)	(1.95)	(0.38)	(0.38)	(0.54)	(1.00)	(0.40)
	Free cash flow	(209.56)	(48.50)	(16.20)	(43.92)	(19.30)	(10.92)	(9.45)	3.84	4.30	6.19
	Book value	179.92	126.45	27.43	(5.98)	(36.09)	(51.29)	(74.41)	(64.33)	(2.53)	25.27
	Shares, m	0	0	1	1	1	1	1	1	1	1
Valuation, ×
Valuation, ×	P/E	0.25	0.25	0.25	0.25	0.25	0.25	0.25	0.25	0.42	0.04
	P/S	0.02	0.02	0.02	0.02	0.02	0.02	0.02	0.02	0.05	0.03
	P/B	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.05
	EV/Sales	0.04	0.04	0.04	0.04	0.04	0.04	0.04	0.04	0.08	0.04
	EV/FCF	0.58	0.58	0.58	0.58	0.58	0.58	0.58	0.58	1.00	0.28
Cash, $m
Cash, $m	Operating cash flow	(8)	(15)	(9)	(19)	(14)	(9)	(8)	4	5	6
	Capex	—	0	0	(14)	(2)	0	0	0	(1)	0
	Free cash flow	(8)	(15)	(9)	(33)	(16)	(9)	(8)	3	4	5
Balance, $m
Balance, $m	Working capital	(12)	12	9	(1)	(4)	(4)	(2)	(1)	1	5
	Total debt	8	—	—	3	—	9	14	4	—	—
	Net debt	7	(15)	(6)	1	(3)	7	9	1	(1)	(3)
	Shareholders’ equity	7	40	15	(4)	(29)	(42)	(63)	(56)	(2)	22
Returns, %
Returns, %	ROA	(15.22)	(25.62)	(29.99)	(65.73)	(60.65)	(35.53)	(80.72)	13.43	44.70	101.07
	ROIC	(29.10)	(15.94)	(84.19)	0.00	0.00	0.00	0.00	0.00	0.00	12.85
	ROE	(85.16)	(52.66)	(45.93)	(495.47)	175.70	41.80	41.63	(3.29)	(21.60)	243.97

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026 · fundamentals updated 28 Sep 2026

Charts ten years each

No peers yet.